611 W. Union Street|
Benson, AZ 85602
Health Choice Integrated Care crisis Line
NurseWise 24-Hour Crisis Line
NAZCARE Warm Line
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...
|Basic InformationLookupsLatest News|A Shot of Caffeine May Speed Wake-Up After AnesthesiaZika Hijacks Pregnant Woman's Immune SystemHernia Patients May Need Fewer Opioids After Surgery, Study FindsHealth Tip: Prevent DehydrationTravel Tips for Contact Lens WearersHigher Odds of Infection With Reduced Kidney FunctionMost Ulcerative Colitis Patients Do Not Achieve Target RemissionOral Contraceptive Use Linked to Lower Rheumatoid Arthritis RiskKidney Disease May Boost Odds of InfectionZika May Not Last in Semen as Long as ThoughtVirtual House Calls for Speedy, Effective Parkinson's CareNearly 4 Million Worldwide Die Each Year From Asthma, COPDPowerful New Cholesterol Med Won't Harm Memory, Easing ConcernsDiverse Spectrum of Neurologic Syndromes Seen With ZikaExposure to Particulate Matter Linked to Metabolic AlterationsAir Purifiers May Help the Smog-Stressed Heart'Fat But Fit' a Myth?Statin Use Among Nursing Home Residents Varies SignificantlyZika Virus Tied to Neurological Woes in AdultsAn Expert's Guide to Preventing Food PoisoningHeart Risk Up if Hospitalized for Pneumonia or SepsisSinging May Be Good Medicine for Parkinson's PatientsCPAP Doesn't Alter Renal Function in Coexisting OSA, CVDWhen Stress Hormone Falters, Your Health May SufferKidney Disease May Boost Risk of Abnormal HeartbeatCertain Jobs Linked to Raised Risk of Rheumatoid ArthritisMidlife Vascular Risk Factors Tied to Increased Risk of DementiaHigher Risk of CVD Persists After Hospital Stay for Severe InfectionAntibiotic Doesn't Prevent Lung Complication After Stem Cell TransplantHealth Tip: One of Three Adults Gets ShinglesBlood Pressure Fluctuations Tied to Dementia Risk in StudyDecline in Kids' Ear Infections Linked to Pneumococcal VaccineFDA Approves Mavyret for Hepatitis CDoes Less Sleep Make You Less Healthy?Diabetes Drug Shows Promise Against Parkinson'sReview Suggests Benefits of Aerobic Exercise in FibromyalgiaNovel Procedure Improves Kidney Transplant SuccessABP 501, Adalimumab Biosimilar, Safe and Effective, for PsoriasisSimilar Defects ID'd for T2DM, Chronic Pancreatitis and DiabetesScientists Gain Insight Into AllergiesHealth Tip: Cooling a Heat RashKnow the Signs of ConcussionDo Your Pearly Whites Sometimes Cause You Pain?Rates of Inflammatory Bowel Disease Down in Rural AreasZika Probably Not Spread Through Saliva: StudyDrug for Kidney Disease Tied to Infection RiskGum Disease May Be Linked to Cancer Risk in Older WomenStent Surgery Could Benefit Select Glaucoma PatientsBlood Proteins Linked to Severity of Chronic Fatigue SyndromeDrowning Can Occur Hours After SwimmingQuestions and AnswersLinksBook Reviews
Lower Risk of Gastrointestinal Bleeding for Apixaban
Updated: Apr 10th 2017
MONDAY, April 10, 2017 (HealthDay News) -- For patients receiving direct oral anticoagulant (DOAC) agents for non-valvular atrial fibrillation, apixaban is associated with a lower risk of gastrointestinal (GI) bleeding than rivaroxaban or dabigatran, according to a study published in the April issue of Gastroenterology.
Neena S. Abraham, M.D., from the Mayo Clinic in Scottsdale, Ariz., and colleagues conducted a retrospective study using administrative claims data of privately insured individuals and Medicare Advantage enrollees. Three propensity-matched cohorts of patients with non-valvular atrial fibrillation with incident exposure to dabigatran, rivaroxaban, or apixaban were created. Data were compared on rivaroxaban versus dabigatran for 31,574 patients; for apixaban versus dabigatran for 13,084 patients; and for apixaban versus rivaroxaban for 13,130 patients.
The researchers found that GI bleeding occurred more often in patients given rivaroxaban versus dabigatran (hazard ratio, 1.2). The risk of GI bleeding was lower for apixaban versus dabigatran or rivaroxaban (hazard ratios, 0.39 and 0.33, respectively). For apixaban and rivaroxaban, the median times to gastrointestinal bleeding were <90 days, while for dabigatran, the median time was <120 days.
"In a population-based study of patients receiving DOAC agents, we found apixaban had the most favorable GI safety profile and rivaroxaban the least favorable profile " the authors write.
This article: Copyright © 2017 HealthDay. All rights reserved.